HS235 vs Sotatercept

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: Activin receptor type IIA (ActRIIA) · full Pulmonary Arterial Hypertension pipeline

HS235

Developed by GlaxoSmithKline and partners

Phase 1/2 in Pulmonary Arterial Hypertensionpeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07143448 (registry estimate)

No aligned efficacy figure on record for this race.

Sotatercept · Winrevair

Marketed by Merck & Co. and partners

Approved in Pulmonary Arterial Hypertensionprotein (ActRIIA-Fc fusion)
Reliable signal

NCT04576988 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 323 treated participants and a clinical primary efficacy endpoint. The primary 6-minute walk distance comparison favored sotatercept and was statistically significant (p<0.001), supporting a strong evidence grade.

Next expected readout: August 2027 · NCT07356778 (registry estimate)

Reported efficacy

Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24); Number of Participants Who Experienced an Adverse Event (AE) (Up to approximately 24 weeks); Number of Participants Who Discontinued Study Treatment Due to an AE (Up to approximately 24 weeks): Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) (met)

Result source: NCT04576988

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HS235: no structured comparison results are available for Pulmonary Arterial Hypertension.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sotatercept

6MWD - Change 53.6 vs 31.4 placebo m @ 24wk0.7 mg/kg
absolute change · m
NCT03496207 · Phase 2 · registry result, not featured evidence
show 3 more results
56 vs 31.4 placebo m @ 24wk0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
34.4 vs 1 placebo m @ 24wk
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
46 vs 22 placebo m @ 24wk
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Multicomponent Improvement 38.9% (n=162) vs 10.1% (n=159) placebo @ 24wk
absolute value · percentage points
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
PVR -165.1 vs 32.8 placebo cm @ 24wk
absolute change · cm
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
show 1 more result
-180 vs -40 placebo cm @ 24wk
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
NT-proBNP -359 vs 195.9 placebo pg/mL @ 24wk0.7 mg/kg
absolute change · pg/mL
NCT03496207 · Phase 2 · registry result, not featured evidence
show 3 more results
-718.2 vs 195.9 placebo pg/mL @ 24wk0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
-230.3 vs 58.6 placebo pg/mL @ 24wk
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
-1336 vs 26 placebo pg/mL @ 24wk
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
WHO FC Improvement 29.4% (n=163) vs 13.8% (n=159) placebo @ 24wk
absolute value · percentage points
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
Time to Death or Clinical Worsening NA vs NA placebo months
time to event · months
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
Low Risk 39.5% (n=162) vs 18.2% (n=159) placebo @ 24wk
absolute value · percentage points
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
PAH Symact Physical Impacts -0.13 vs 0.01 placebo score @ 24wk
absolute change · score
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
PAH Symact Cardiopulmonary Symptoms -0.12 vs -0.01 placebo score @ 24wk
absolute change · score
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
PAH Symact Cognitive/Emotional Impacts 0 vs 0.000007 placebo score @ 24wk
absolute change · score
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
Time to First Morbidity or Mortality Event NA vs 9.6 placebo months
time to event · months
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
Overall Survival NA vs NA placebo months
time to event · months
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3

+ 25 further endpoints in the CSV export.

Available safety results

Sotatercept

Dropout rate
2.5%Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
show 14 more results
—Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
—Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
19.8%
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Sotatercept - Extension Treatment
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Sotatercept - Primary Treatment Pe
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
4.8%
NCT03738150 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
14.3%0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
3.1%0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.6%Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
show 14 more results
—Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
—Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
1.2%
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Sotatercept - Extension Treatment
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Sotatercept - Primary Treatment Pe
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—
NCT03738150 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
9.5%0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
3.1%0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
Serious AEs
—Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
show 14 more results
14.1%Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
16.5%Sotatercept Plus Background PAH Th
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
60.5%
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
4.4%Sotatercept - Extension Treatment
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
13%Sotatercept - Primary Treatment Pe
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—
NCT03738150 · Phase 2 · registry result, not featured evidence
23.8%0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
26.7%0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
33.3%0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
6.3%0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
40%0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
32.3%0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
—0.3 mg/kg
NCT03496207 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
headache 20.2% (placebo 15%)
covid-19 14.7% (placebo 11.9%)
diarrhoea 12.3% (placebo 7.5%)
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
show 10 more results
epistaxis 15.8% (placebo 1.9%)
covid-19 15.2% (placebo 11.9%)
telangiectasia 7.6% (placebo 3.1%)
NCT04576988 · Phase 3 · combination · Pulmonary Arterial Hypertension · phase 3
epistaxis 45.3% (placebo 7%)
headache 26.7% (placebo 25.6%)
diarrhoea 25.6% (placebo 17.4%)
NCT04896008 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
nasopharyngitis 15.6%
epistaxis 11.1%
haemoglobin increased 6.7%
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
nasopharyngitis 30.4%
headache 21.7%
epistaxis 17.4%
NCT05818137 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
0.7 mg/kg
haemoglobin increased 16.7% (placebo 0%)
diarrhoea 14.3% (placebo 15.6%)
headache 14.3% (placebo 18.8%)
NCT03496207 · Phase 2 · registry result, not featured evidence
0.7 mg/kg
headache 46.7% (placebo 18.8%)
nasopharyngitis 40% (placebo 9.4%)
oedema peripheral 40% (placebo 15.6%)
NCT03496207 · Phase 2 · registry result, not featured evidence
0.7 mg/kg
oedema peripheral 19.4% (placebo 15.6%)
telangiectasia 19.4% (placebo 0%)
headache 16.7% (placebo 18.8%)
NCT03496207 · Phase 2 · registry result, not featured evidence
0.3 mg/kg
headache 25% (placebo 18.8%)
diarrhoea 21.9% (placebo 15.6%)
dizziness 15.6% (placebo 9.4%)
NCT03496207 · Phase 2 · registry result, not featured evidence
0.3 mg/kg
fatigue 40% (placebo 18.8%)
nasopharyngitis 33.3% (placebo 9.4%)
dizziness 26.7% (placebo 9.4%)
NCT03496207 · Phase 2 · registry result, not featured evidence
0.3 mg/kg
oedema peripheral 35.5% (placebo 15.6%)
nasopharyngitis 32.3% (placebo 9.4%)
diarrhoea 29% (placebo 15.6%)
NCT03496207 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS235's landscape · Sotatercept's landscape